Last10K.com

Adolor Corp (ADLR) SEC Filing 10-Q Quarterly report for the period ending Wednesday, June 30, 2010

Adolor Corp

CIK: 1076167 Ticker: ADLR

Exhibit 99.1

 

GRAPHIC

 

GRAPHIC

 

FOR IMMEDIATE RELEASE

 

Contact:

Adolor Corporation

Stephen W. Webster

Senior Vice President, Finance and CFO

(484) 595-1500

 

ADOLOR CORPORATION REPORTS

 

SECOND QUARTER 2010 FINANCIAL RESULTS

 

EXTON, PA, July 29, 2010

— Adolor Corporation (NasdaqGM: ADLR) today reported a net loss of $8.3 million, or $(0.18) per basic and diluted share, for the three months ended June 30, 2010, compared to a net loss of $16.5 million, or $(0.36) per basic and diluted share, for the three months ended June 30, 2009.  For the six months ended June 30, 2010, Adolor reported a net loss of $17.9 million, or $(0.39) per basic and diluted share, compared to a net loss of $29.7 million, or $(0.64) per basic and diluted share, for the six months ended June 30, 2009.

 

As previously announced, net product sales of ENTEREG® (alvimopan) were $6.3 million and $2.4 million for the three months ended June 30, 2010 and 2009, respectively, and $11.5 million and $3.8 million for the six months ended June 30, 2010 and 2009, respectively.  The increase in net product sales during the three and six months ended June 30, 2010 as compared to the prior year periods resulted from an increase in the number of hospitals ordering ENTEREG and increased penetration within existing hospital customers.  Net product sales for the three and six months ended June 30, 2010 were recognized at the time of shipment as compared to net product sales for the three and six months ended June 30, 2010, which were recognized on a reorder basis under the Company’s previous revenue recognition policy.  Net shipments of ENTEREG for the three and six months ended June 30, 2009 were $2.9 million and $4.9 million, respectively.

 

Cash, cash equivalents and short-term investments at June 30, 2010 were $62.3 million, which the Company believes will fund currently anticipated operating activities through 2012.

 

“The second quarter saw continued progress with ENTEREG and the advancement of our OBD compounds in early clinical evaluation,” said Michael R. Dougherty, President and Chief Executive Officer.  “Following our recently announced restructuring, Adolor enters the second half of 2010 well positioned with a growing commercial product, a promising clinical development program and a reduced burn rate.”

 


The following information was filed by Adolor Corp (ADLR) on Thursday, July 29, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Adolor Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adolor Corp.

Continue

Assess how Adolor Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adolor Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2010 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: ADLR
CIK: 1076167
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-10-170158
Submitted to the SEC: Thu Jul 29 2010 11:10:23 AM EST
Accepted by the SEC: Thu Jul 29 2010
Period: Wednesday, June 30, 2010
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/adlr/0001193125-10-170158.htm